1. Introduction

   • Richard Pazdur

   OriginalPaper Pages: 297 - 298

2. 5-Fluorouracil: Forty-Plus and Still Ticking. A Review of its Preclinical and Clinical Development

   • Jean L. Grem

   OriginalPaper Pages: 299 - 313

3. Conceptual Changes in Cancer Chemotherapy: From an Oral Fluoropyrimidine Prodrug, UFT, to a Novel Oral Fluoropyrimidine Prodrug, S-1, and Low-Dose FP Therapy in Japan

   • Tetsuhiko Shirasaka
   • Susumu Yamamitsu
   • Tetsuo Taguchi

   OriginalPaper Pages: 315 - 329

4. The Tegafur-Based Dihydropyrimidine Dehydrogenase Inhibitory Fluoropyrimidines, UFT/Leucovorin (ORZEL and S-1: a Review of Their Clinical Development and Therapeutic Potential

   • Paulo M. Hoff

   OriginalPaper Pages: 331 - 342

5. Capecitabine: Preclinical Pharmacology Studies

   • Hideo Ishitsuka

   OriginalPaper Pages: 343 - 354

6. Capecitabine

   • Daniel R. Budman

   OriginalPaper Pages: 355 - 363

7. Preclinical Development of Eniluracil: Enhancing the Therapeutic Index and Dosing Convenience of 5-Fluorouracil

   • Melanie T. Paff
   • David P. Baccanari
   • Thomas Spector

   OriginalPaper Pages: 365 - 371

8. Pharmacology of Fluorinated Pyrimidines: Eniluracil

   • Sharyn D. Baker

   OriginalPaper Pages: 373 - 381

9. Clinical Development of Eniluracil/Fluorouracil: an Oral Treatment for Patients with Solid Tumors

   • Jeremey Levin
   • John Hohneker

   OriginalPaper Pages: 383 - 390

10. Volume Contents

    Volume Contents Pages: 391 - 393